Endocrine Biomarkers
Endocrine disorders such as diabetes, thyroid disease, adrenal insufficiency and metabolic syndromes are highly prevalent in New Zealand and contribute substantially to chronic disease burden, disability and long-term health costs. The most recent estimates suggest that around 348,500 people in Aotearoa live with diabetes, with prevalence rising steadily over the past decade and higher rates seen in Pacific and Māori populations. Accurate and timely measurement of endocrine biomarkers such as fasting glucose, HbA1c, insulin, thyroid stimulating hormone (TSH) and cortisol is essential for diagnosing disease, monitoring therapy and guiding clinical interventions.
Translyx is introducing a range of innovative endocrinology biomarker solutions designed to improve diagnostic accuracy, reduce turnaround times, and integrate with routine clinical workflows in hospitals and outpatient settings. These technologies support earlier identification of metabolic dysfunction, better monitoring of treatment response, and more personalised management of endocrine conditions. For primary care clinicians, endocrinologists and community health teams, improved biomarker access helps close gaps in disease detection and management, particularly in underserved regions where diabetes and metabolic disorders are most common.